Clarity Pharmaceuticals Says Diagnostic Candidate Identifies Greater Number of Lesions Per Participant in Prostate Cancer Trial

MT Newswires Live

Yesterday

Clarity Pharmaceuticals (ASX:CU6) said that its copper-64-SAR-bisPSMA diagnostic candidate identified a "statistically significant" greater number of lesions per participant than standard-of-care gallium-68-PSMA-11 positron emission tomography (PET)/computed tomography (CT) in the Co-PSMA investigator-initiated trial, according to a Monday Australian bourse filing.

The phase two trial evaluated the performance of Clarity's diagnostic candidate, copper-64-SAR-bisPSMA, in comparison with gallium-68-PSMA-11 in 50 prostate cancer patients with biochemical recurrence of prostate cancer following radical prostatectomy, who were candidates for curative salvage therapy.

The mean per-patient lesion was 1.3 for copper-64-SAR-bisPSMA PET/CT, compared with 0.5 for gallium-68-PSMA-11, with a difference of 0.8. In total, gallium-68-PSMA-11 identified 24 lesions across all participants, while copper-64-SAR-bisPSMA next-day imaging detected 63 lesions.

At a per-patient level, gallium-68-PSMA-11 identified 36% of trial participants as having a positive scan, while copper-64-SAR-bisPSMA next-day imaging detected prostate cancer in 78% of cases.

The data outlining results from the Co-PSMA trial will be presented at the EAU Congress 2026 in London.

Clarity Pharmaceuticals' shares jumped nearly 18% in recent trading on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2611170618"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611170618\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611170618?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-16 11:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611170618","market":"nz","top_or_hot":-1,"title":"Clarity Pharmaceuticals Says Diagnostic Candidate Identifies Greater Number of Lesions Per Participant in Prostate Cancer Trial","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> (ASX:CU6) said that its copper-64-SAR-bisPSMA diagnostic candidate identified a \"statistically significant\" greater number of lesions per participant than standard-of-care gallium-68-PSMA-11 positron emission tomography (PET)/computed tomography (CT) in the Co-PSMA investigator-initiated trial, according to a Monday Australian bourse filing.</p><p>The phase two trial evaluated the performance of Clarity's diagnostic candidate, copper-64-SAR-bisPSMA, in comparison with gallium-68-PSMA-11 in 50 prostate cancer patients with biochemical recurrence of prostate cancer following radical prostatectomy, who were candidates for curative salvage therapy.</p><p>The mean per-patient lesion was 1.3 for copper-64-SAR-bisPSMA PET/CT, compared with 0.5 for gallium-68-PSMA-11, with a difference of 0.8. In total, gallium-68-PSMA-11 identified 24 lesions across all participants, while copper-64-SAR-bisPSMA next-day imaging detected 63 lesions.</p><p>At a per-patient level, gallium-68-PSMA-11 identified 36% of trial participants as having a positive scan, while copper-64-SAR-bisPSMA next-day imaging detected prostate cancer in 78% of cases.</p><p>The data outlining results from the Co-PSMA trial will be presented at the EAU Congress 2026 in London.</p><p>Clarity Pharmaceuticals' shares jumped nearly 18% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clarity Pharmaceuticals Says Diagnostic Candidate Identifies Greater Number of Lesions Per Participant in Prostate Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClarity Pharmaceuticals Says Diagnostic Candidate Identifies Greater Number of Lesions Per Participant in Prostate Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-16 11:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> (ASX:CU6) said that its copper-64-SAR-bisPSMA diagnostic candidate identified a \"statistically significant\" greater number of lesions per participant than standard-of-care gallium-68-PSMA-11 positron emission tomography (PET)/computed tomography (CT) in the Co-PSMA investigator-initiated trial, according to a Monday Australian bourse filing.</p><p>The phase two trial evaluated the performance of Clarity's diagnostic candidate, copper-64-SAR-bisPSMA, in comparison with gallium-68-PSMA-11 in 50 prostate cancer patients with biochemical recurrence of prostate cancer following radical prostatectomy, who were candidates for curative salvage therapy.</p><p>The mean per-patient lesion was 1.3 for copper-64-SAR-bisPSMA PET/CT, compared with 0.5 for gallium-68-PSMA-11, with a difference of 0.8. In total, gallium-68-PSMA-11 identified 24 lesions across all participants, while copper-64-SAR-bisPSMA next-day imaging detected 63 lesions.</p><p>At a per-patient level, gallium-68-PSMA-11 identified 36% of trial participants as having a positive scan, while copper-64-SAR-bisPSMA next-day imaging detected prostate cancer in 78% of cases.</p><p>The data outlining results from the Co-PSMA trial will be presented at the EAU Congress 2026 in London.</p><p>Clarity Pharmaceuticals' shares jumped nearly 18% in recent trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CPXR","symbol_name":"USCF DAILY TARGET 2X COPPER INDEX ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2611170618","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611170618","pubTimestamp":1771211535,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clarity Pharmaceuticals  said that its copper-64-SAR-bisPSMA diagnostic candidate identified a \"statistically significant\" greater number of lesions per participant than standard-of-care gallium-68-PSMA-11 positron emission tomography /computed tomography  in the Co-PSMA investigator-initiated trial, according to a Monday Australian bourse filing.The phase two trial evaluated the performance of Clarity's diagnostic candidate, copper-64-SAR-bisPSMA, in comparison with gallium-68-PSMA-11 in 50 prostate cancer patients with biochemical recurrence of prostate cancer following radical prostatectomy, who were candidates for curative salvage therapy.The mean per-patient lesion was 1.3 for copper-64-SAR-bisPSMA PET/CT, compared with 0.5 for gallium-68-PSMA-11, with a difference of 0.8. In total, gallium-68-PSMA-11 identified 24 lesions across all participants, while copper-64-SAR-bisPSMA next-day imaging detected 63 lesions.At a per-patient level, gallium-68-PSMA-11 identified 36% of trial par","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CPXR":"USCF DAILY TARGET 2X COPPER INDEX ETF","BK4535":"淡马锡持仓","COPJ":"SPROTT JUNIOR COPPER MINERS ETF","BK7096":"制药","CPER":"美国铜指数基金","XME":"金属与采矿指数ETF-SPDR","BK7047":"环境与设施服务","CU6.AU":"CLARITY PHARMACEUTICALS LTD","PET.AU":"PHOSLOCK ENVIRONMENTAL TECHN"},"translate_title":"Clarity Pharmaceuticals表示，在前列腺癌试验中，诊断候选药物可识别出每位参与者更多的病变","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPER":0.8,"QCmain":0.8,"COPJ":0.8,"CPXR":0.8,"PET.AU":1,"CU6.AU":1,"MHGmain":0.8,"XME":0.8},"content_text":"Clarity Pharmaceuticals (ASX:CU6) said that its copper-64-SAR-bisPSMA diagnostic candidate identified a \"statistically significant\" greater number of lesions per participant than standard-of-care gallium-68-PSMA-11 positron emission tomography (PET)/computed tomography (CT) in the Co-PSMA investigator-initiated trial, according to a Monday Australian bourse filing.The phase two trial evaluated the performance of Clarity's diagnostic candidate, copper-64-SAR-bisPSMA, in comparison with gallium-68-PSMA-11 in 50 prostate cancer patients with biochemical recurrence of prostate cancer following radical prostatectomy, who were candidates for curative salvage therapy.The mean per-patient lesion was 1.3 for copper-64-SAR-bisPSMA PET/CT, compared with 0.5 for gallium-68-PSMA-11, with a difference of 0.8. In total, gallium-68-PSMA-11 identified 24 lesions across all participants, while copper-64-SAR-bisPSMA next-day imaging detected 63 lesions.At a per-patient level, gallium-68-PSMA-11 identified 36% of trial participants as having a positive scan, while copper-64-SAR-bisPSMA next-day imaging detected prostate cancer in 78% of cases.The data outlining results from the Co-PSMA trial will be presented at the EAU Congress 2026 in London.Clarity Pharmaceuticals' shares jumped nearly 18% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}